登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis
ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由复旦大学附属肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07150208,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 70 岁;性别:仅女性
登记记录的入选字段
Histologically confirmed invasive HER2-low expressing breast cancer (specific definition: breast cancer patients with low expression of human epidermal growth factor receptor 2 (HER-2) as determined by pathological testing. Specifically: HER2 IHC 1+ or HER2 IHC++ with FISH/CISH negative. All specimens must be verified by the pathology department of the research participating center.
入选标准第 3 条
Received no more than 2 lines of chemotherapy after metastasis.
入选标准第 7 条
HR-positive patients must have previously received CDK4/6 inhibitor treatment, whether in the adjuvant treatment phase or in the recurrent metastatic phase.
入选标准第 8 条
Female subjects with reproductive capacity need to use one medically recognized contraceptive method during the study treatment period and for at least 3 months after the last use of the study drug.
入选标准第 14 条
Received more than 2 lines of chemotherapy.
排除标准第 1 条
ECOG score of 0 to 1.
入选标准第 1 条
Blood routine examination standards must comply with: HB≥90g/L (not transfused within 14 days); ANC≥1.5×10\^9/L; PLT≥75×10\^9/L;
入选标准第 11 条
Biochemical examination must comply with the following standards: TBIL≤1.5×ULN (upper limit of normal); ALT and AST≤3×ULN; if there is liver metastasis, ALT and AST≤5×ULN; serum Cr ≤1.5×ULN, endogenous creatinine clearance rate ≥30mL/min.
入选标准第 12 条
History of other malignancies within the past 5 years, excluding cured cervical carcinoma in situ, skin basal cell carcinoma, or skin squamous cell carcinoma.
排除标准第 8 条
Known HBV or HCV infection during the active phase or HBV DNA ≥500, or chronic phase with abnormal liver function.
排除标准第 13 条
Active primary immunodeficiency, known HIV test positive.
排除标准第 14 条
Pregnant patients.
排除标准第 7 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07150208,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
ECOG score of 0 to 1. Expected survival period greater than 12 weeks. Histologically confirmed invasive HER2-low expressing breast cancer (specific definition: breast cancer patients with low expression of human epidermal growth factor receptor 2 (HER-2) as determined by pathological testing. Specifically: HER2 IHC 1+ or HER2 IHC++ with FISH/CISH negative. All specimens must be verified by the pathology department of the research participating center. Tumor stage: recurrent or metastatic breast cancer; local recurrence must be confirmed by the researcher to be unable to undergo radical surgical resection. Patients must have at least one lesion that has not previously received radiation therapy (measurable and/or non-measurable). MRI or CT shows brain metastasis and meets one of the following conditions: Received no more than 2 lines of chemotherapy after metastasis. HR-positive patients must have previously received CDK4/6 inhibitor treatment, whether in the adjuvant treatment phase or in the recurrent metastatic phase. Never used T-DXd or bevacizumab before. The main organ functions are basically normal, meeting the following conditions: Blood routine examination standards must comply with: HB≥90g/L (not transfused within 14 days); ANC≥1.5×10\^9/L; PLT≥75×10\^9/L; Biochemical examination must comply with the following standards: TBIL≤1.5×ULN (upper limit of normal); ALT and AST≤3×ULN; if there is liver metastasis, ALT and AST≤5×ULN; serum Cr ≤1.5×ULN, endogenous creatinine clearance rate ≥30mL/min. Allowed to use mannitol, hormone therapy before enrollment, but the drug treatment dose can be stable for at least one week without the need for an increase. Female subjects with reproductive capacity need to use one medically recognized contraceptive method during the study treatment period and for at least 3 months after the last use of the study drug. Subjects voluntarily join this study, sign an informed consent form, have good compliance, and cooperate with follow-up.排除标准:Exclusion Criteria:
Received more than 2 lines of chemotherapy. Used T-DXd or bevacizumab. Meningeal metastasis. Brain metastasis requiring emergency intervention treatment, or brain metastasis requiring treatment with more than 3mg/d of dexamethasone or equivalent medication. Clinical significant or uncontrolled cardiac disease history, including congestive heart failure, angina, myocardial infarction within the past 6 months, or ventricular arrhythmia. Ongoing adverse reactions of grade >1 due to previous treatment. The exception is alopecia or those that the researcher believes should not be excluded. Such cases should be clearly documented in the investigator's notes. Pregnant patients. History of other malignancies within the past 5 years, excluding cured cervical carcinoma in situ, skin basal cell carcinoma, or skin squamous cell carcinoma. Inability to swallow, chronic diarrhea, and intestinal obstruction, with multiple factors affecting drug intake and absorption. Third space fluid accumulation (such as massive pleural effusion and ascites) that cannot be controlled by drainage or other methods. Participated in another antitumor drug clinical trial within 4 weeks before the first administration of the study drug. Long-term non-healing wounds or incompletely healed fractures. Known HBV or HCV infection during the active phase or HBV DNA ≥500, or chronic phase with abnormal liver function. Active primary immunodeficiency, known HIV test positive. Uncontrolled infection requiring intravenous antibiotics, antiviral drugs, or antifungal drugs. History of (non-infectious) ILD/pneumonia requiring steroids, currently having ILD/pneumonia, or unable to exclude suspected ILD/pneumonia on imaging during screening. Pulmonary criteria: Clinically significant pulmonary comorbidities, including but not limited to any underlying pulmonary disease (e.g., pulmonary embolism, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc.) within 3 months of study recruitment. Any autoimmune disease, connective tissue disease, or inflammatory disease (e.g., rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc.) with recorded or suspected pulmonary involvement during screening. All detailed information about the disease should be recorded in the CRF for participants in the study. Previous total pneumonectomy. Allergic constitution, or known history of allergy to any component of the study regimen, or allergic to other monoclonal antibodies. History of gastrointestinal bleeding within the past 6 months or a clear tendency for gastrointestinal bleeding, such as: esophageal varices at risk of bleeding, local active ulcer lesions, fecal occult blood ≥ (++) not eligible for enrollment; if fecal occult blood (+), gastroscopy is required; Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days before participating in this study; Urinalysis shows urine protein ≥++ or confirmed 24-hour urine protein quantitative >1.0g; Hypertension, and blood pressure cannot be lowered to the normal range with antihypertensive drugs (systolic blood pressure >140mmHg, diastolic blood pressure >90mmHg). Substance abuse or medical conditions that the researcher believes may interfere with the subject's participation in the clinical study or the assessment of the clinical study results.
引自 ClinicalTrials.gov, NCT07150208, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07150208,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。